AstraZeneca PLC

AZN

206.76 (0.84%) 1.74

Health Care

Pharmaceuticals

AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company offers Imjudo Datroway Iressa Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Farxiga Brilinta Crestor Seloken Lokelma Roxadustat Andexxa Wainua Symbicort Fasenra Pulmicort Breztri/Trixeo Saphnelo Tezspire Airsupra Ultomiris Soliris Strensiq Koselugo Kanuma Atacand Plendil Modip Splendil Munobal Flodil Komboglyze Qtern Byetta XIGDUO Accolate Accoleit Vanticon Beyfortus Synagis FluMist tixagevimab and cilgavimab and sipavibart. It also provides Bricanyl Respules Eklira Genuair/Tudorza/Bretaris Bricanyl Turbuhaler Rhinocort Bevespi Aerosphere Daliresp/Daxas Oxis Turbuhaler Breztri Aerosphere Duaklir Genuair Kavigale Evusheld Fluenz/FluMist and Voydeya. The company offers its products for ocology cardiovascular renal and metabolism respiratory & immunology vaccines and immune and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom the United States Europe and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare life sciences and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates with the potential to treat diseases across multiple indications and multiple next-generation therapies for obesity and type 2 diabetes; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.

Quality Checklist 5/8

ROIC > 10%

Debt/Equity < 1

Net Margin > 10%

Past Net Income CAGR > 0%

Est. EPS Growth > 5%

5Y Shares Out Change < 0%

Current Ratio > 1

Quick Ratio > 1

0.0%of Portfolio

My holdings

Day change:

Total change:

Cost basis:

Market cap: $320.67(B)

EV: $337.73(B)

Total Equity: $48.72(B)

Earnings date: Apr-29-2026

P/E: 31.33

Forward P/E: 20.07

P/FCF: 27.24

P/S: 5.46

P/B: 6.59

EPS: $6.6

EPS (fwd): $10.3

FCF/share: $7.6

Revenue/share: $37.9

Book value/share: $31.4

ROIC: 12.5%

ROA: 8.6%

ROE: 21.7%

Debt/Equity: 0.61

Current Ratio: 0.90

Gross margin: 81.7%

Operating margin: 22.0%

Net margin: 17.4%

Dividend/share: $3.2

Div. yield: 1.55%

All Valuation Overview Growth Financials & KPIs Competitors & Peer Comparison Ownership Tools

AZN Valuation & Price Targets

Current Price

$207

Favorite Valuation Methods

PEvaluation

N/A

Analyst targets

N/A

DCF (2-stage)

N/A

More Valuation Methods

DCF (simple)

N/A

DCF (exit mult.)

N/A

DDM

N/A

EPS growth

N/A

Revenue growth

N/A

Peter Lynch FV

N/A

Graham No.

N/A

PEvaluation

46% overvalued

Low

$84

Mid

$112

High

$140

Current price

$207

Fair P/E

Margin of safety

EPS

Market Model

Economic moat: None/narrow

EPS Estimates

	Low	Avg	High	#
FY+1	10.0	10.3	10.6	19
FY+2	11.1	11.6	12.6	19
FY+3	11.5	12.7	14.3	13
FY+4	12.1	13.9	16.0	7
FY+5	12.8	15.2	17.2	7

Analyst Price Targets

N/A
No analyst price targets

Analyst Recommendations

Strong Buy4

Buy15

Hold2

Sell1

Strong Sell1

2-stage DCF

First Stage Duration: 5 Years

Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh

Terminal Growth Rate
LowMidHigh

Discount Rate

Discounted Cash Flow

Forecast years: 5 Years

Terminal Growth Rate
LowMidHigh

Discount Rate

Free cash flow estimates:

Y+1 est.

Y+2 est.

0.00%

Y+3 est.

0.00%

Y+4 est.

0.00%

Y+5 est.

0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years

Exit FCF Multiple
LowMidHigh

Discount Rate

Free cash flow estimates:

Y+1 est.

Y+2 est.

0.00%

Y+3 est.

0.00%

Y+4 est.

0.00%

Y+5 est.

0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years

First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years

Starting EPS
EPS Growth Rate
LowMidHigh

Final P/E
LowMidHigh

Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years

Base Revenue
Revenue Growth Rate
LowMidHigh

Final Net Margin
LowMidHigh

Final P/E Ratio
LowMidHigh

Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate

About

Terms & privacy

Price charts & news courtesy of TradingView

Blog

Contact